Trials / Withdrawn
WithdrawnNCT02215629
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
A Phase I Dose Escalation Study of VS-4718, A Focal Adhesion Kinase Inhibitor, In Subjects With Relapsed or Refractory Acute Myeloid Leukemia or B-Cell Acute Lymphoblastic Leukemia
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Verastem, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to test the safety and efficacy of VS-4718 in two types of leukemia patients and to find the right dose of VS-4718 for future clinical trials. Other purposes of this study include: * Testing for study drug VS-4718 levels in blood over time and what happens to the study drug in patients. * To find out if there are certain biomarkers in leukemia patients that predict if and how 4718 study drug may or may not work.
Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VS-4718 |
Timeline
- Primary completion
- 2016-09-01
- Completion
- 2016-11-01
- First posted
- 2014-08-13
- Last updated
- 2017-01-27
Source: ClinicalTrials.gov record NCT02215629. Inclusion in this directory is not an endorsement.